Trial
NCT00161564
A Trial to Treat Patients With ITP Who Do Not Achieve a Durable Response to Rituxan Alone
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Weill Medical College of Cornell University
Collaborators
Genentech, Inc.
Condition
Idiopathic Thrombocytopenic Purpura (ITP)
Intervention
Rituximab
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-07-17